![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif)
sirolimus A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | rapamycin | | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | Rapamune | | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | Abbreviations: | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | RAPA SLM | | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | AY 22989 SILA 9268A WY-090217 | | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure name: | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) | 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2 | | ![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509173826im_/http://www.cancer.gov/images/spacer.gif) |